Compare Abeona Therapeutics Inc (ABEO) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs BioNTech SE - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while BioNTech SE - ADR trades at $92.73 (market cap $23.84B). The key difference: BioNTech SE - ADR is far larger — about 63.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | BNTX | |
|---|---|---|
Market Cap | $373.32M | $23.84B |
Sector | Health | Health |
52-Week High | $7.23 | $119.34 |
52-Week Low | $4.17 | $83.89 |
Enterprise Value | $228.22M | $7.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BioNTech (BNTX) trades at $94.29, down 3.34% on the day, as the company navigates its transition from COVID-19 vaccine dominance to oncology focus. The stock shows a bullish technical signal with strong analyst support (87.5% buy ratings) and a $130.83 consensus price target. However, fundamental challenges persist with negative net income margins (-44.64%) and declining revenues from pandemic peak levels, offset by a robust $16.78 billion cash position and ongoing $1 billion share repurchase program.
The outlook balances promising oncology pipeline developments against near-term profitability challenges. Investment opportunity lies in BioNTech's cash-rich balance sheet and advancing cancer therapeutics, while risks include execution uncertainty in the therapeutic transition, manufacturing restructuring costs, and competitive pressure in the oncology space. The stock presents a high-risk, high-reward proposition for investors betting on successful pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
